secwatch / observer
8-K filed December 15, 2023, 6:59 PM ET ticker CING CIK 0001862150
other material confidence high sentiment negative materiality 0.85

Cingulate CFO & GC resign; pauses CTx-1301 trial; CEO salary cut 55%; warns of capital need

Cingulate Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Craig S. Gilgallon

General Counsel
CING · Cingulate Inc.
Effective
2023-12-15
Filed
December 15, 2023, 6:59 PM ET
On December 12, 2023, Craig S. Gilgallon, General Counsel, informed Cingulate Inc. (the “Company”) that he was resigning as an officer of the Company and was terminating employment with Cingulate Therapeutics LLC, a wholly-owned subsidiary of the Company, effective on December 15, 2023.
Departed

Gregg Givens

Director
CING · Cingulate Inc.
Filed
December 15, 2023, 6:59 PM ET
On December 13, 2023, each of Gregg Givens and Curt Medeiros provided the Company with notice of their resignation from the Board of Directors.
Departed

Curt Medeiros

Director
CING · Cingulate Inc.
Filed
December 15, 2023, 6:59 PM ET
On December 13, 2023, each of Gregg Givens and Curt Medeiros provided the Company with notice of their resignation from the Board of Directors.
Departed

Patrick Gallagher

Director
CING · Cingulate Inc.
Filed
December 15, 2023, 6:59 PM ET
On December 12, 2023, Patrick Gallagher provided the Company with notice of his resignation from the Board of Directors.
Departed

Louis G. Van Horn

Chief Financial Officer
CING · Cingulate Inc.
Effective
2023-12-13
Filed
December 15, 2023, 6:59 PM ET
On December 13, 2023, Louis G. Van Horn, Chief Financial Officer, retired from the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Craig S. Gilgallon resigned as General Counsel at Cingulate Inc..

Action
resigned
Role
General Counsel
Exact text from the filing
On December 12, 2023, Craig S. Gilgallon, General Counsel, informed Cingulate Inc. (the “Company”) that he was resigning as an officer of the Company and was terminating employment with Cingulate Therapeutics LLC, a wholly-owned subsidiary of the Company, effective on December 15, 2023.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Gregg Givens resigned as Director at Cingulate Inc..

Action
resigned
Role
Director
Exact text from the filing
On December 13, 2023, each of Gregg Givens and Curt Medeiros provided the Company with notice of their resignation from the Board of Directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Curt Medeiros resigned as Director at Cingulate Inc..

Action
resigned
Role
Director
Exact text from the filing
On December 13, 2023, each of Gregg Givens and Curt Medeiros provided the Company with notice of their resignation from the Board of Directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Patrick Gallagher resigned as Director at Cingulate Inc..

Action
resigned
Role
Director
Exact text from the filing
On December 12, 2023, Patrick Gallagher provided the Company with notice of his resignation from the Board of Directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Louis G. Van Horn retired as Chief Financial Officer at Cingulate Inc..

Action
retired
Role
Chief Financial Officer
Exact text from the filing
On December 13, 2023, Louis G. Van Horn, Chief Financial Officer, retired from the Company, effective immediately.
View on SEC.gov

Cingulate Inc. filing history →

Source: SEC EDGAR
accession 0001493152-23-044970
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.